Immatics Announces First Quarter 2023 Financial Results and Business Update
- ACTengine® IMA203 TCR-T monotherapy against PRAME showed
67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off - Objective responses observed across multiple tumor types including checkpoint-refractory cutaneous melanoma, platinum-resistant ovarian cancer, uveal melanoma, head and neck cancer and synovial sarcoma
- Cohort A IMA203 monotherapy TCR-T treatment continues to show manageable tolerability with no high-grade CRS and no ICANS
- Next data update and projected pathway towards registration-directed trials planned for 4Q 2023
- Expansion of cell therapy manufacturing capabilities with construction of an in-house GMP manufacturing facility for registration-directed and initial commercial production of ACTengine® TCR-T products expected to be operational in 2024
- CTA for TCER® IMA402, a novel TCR Bispecific construct targeting PRAME, submitted to German regulatory authorities in April; clinical trial expected to start in 2H 2023 with first clinical data in 2024
- Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to develop four TCR-based adoptive cell therapies targeting solid tumors; Immatics received an option payment of
$15 million and is eligible for up to$490 million in milestone payments in addition to tiered royalties on net sales of the product - Cash and cash equivalents as well as other financial assets not including the recent option payment by Bristol Myers Squibb amount to
$358.7 million 1 (€329.8 million ) as of March 31, 2023, and continued projected cash runway into 2025
Tuebingen, Germany and Houston, TX, May 16, 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2023.
Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics commented, “We commenced 2023 with significant advances in our ACTengine® IMA203 clinical trial, announcing encouraging data demonstrating that IMA203 is able to drive deep and durable responses independent of tumor type, with some responses ongoing beyond 9 months after treatment. As we continue to leverage the multi-cancer PRAME opportunity, we are pleased to have filed a CTA for IMA402, moving our second TCR Bispecifics candidate toward clinical evaluation. We look forward to providing a next update on our IMA203 TCR-T therapy candidates as well as announcing a potential fast-to-market pathway by the end of the year.”
First Quarter 2023 and Subsequent Company Progress
Adoptive Cell Therapy Programs
ACTengine® IMA203 TCR-T monotherapy (Phase 1b Cohort A):
- On May 2nd, Immatics provided an interim update covering data from 11 heavily pre-treated patients in Phase 1b dose expansion Cohort A (monotherapy). Patients were infused with IMA203 TCR-T cells at dose level (DL) 4 or DL5 with a mean total infused dose of 3.67x109 TCR-T cells (range 1.30-8.84x109 TCR-T cells).
- Treatment with IMA203 in Cohort A (monotherapy) continues to show manageable tolerability at doses of up to approximately 9 billion CD8+ TCR-T cells; no high-grade cytokine release syndrome (CRS) and no immune effector cell associated neurotoxicity syndrome (ICANS) observed in the 11 patients treated in Cohort A; no dose-dependent increase of CRS observed.
- All 11 patients experienced expected cytopenia (Grade 1-4) associated with lymphodepletion. 10 patients (
91% ) had a low to moderate (Grade 1-2) cytokine release syndrome (CRS), of which 5 patients (45% ) had Grade 1, and 5 patients (45% ) had Grade 2 CRS. - Objective responses were observed in last-line solid cancer patients including cutaneous melanoma, ovarian cancer, uveal melanoma, head and neck cancer and synovial sarcoma.
- Initial objective response rate (ORR) of
64% (7/11) was observed at ~week 6 (partial responses (PR) according to RECIST 1.1). - Confirmed ORR of
67% (6/9) was observed at ~month 3; initial responses at week 6 were confirmed for all 6 responders with an available subsequent 3-month scan. - Median duration of response2 was not reached (min 1.3+ months, max 8.8+ months) at a median follow-up3 of 8.5 months; two confirmed partial responses (cPR) ongoing at more than 9 months after treatment as well as three additional ongoing responses at 6+ months, ~3 months and 6+ weeks.
- Objective responses were observed independent of solid tumor type at low, medium and high PRAME expression levels above Immatics’ MS-guided RNA threshold.
In addition to Cohort A (IMA203 monotherapy), ACTengine® IMA203 TCR-T is currently being evaluated in two additional ongoing Phase 1b dose expansion cohorts:
- Cohort B: IMA203 in combination with an immune checkpoint inhibitor. Cohort B is focused on generating safety data for potential further investigation of a combination approach as a front-line therapy.
- Cohort C: IMA203CD8 TCR-T monotherapy, where IMA203 engineered T cells are co-transduced with a CD8αβ co-receptor. IMA203CD8 is currently being explored in DL4a (up to 0.8x109 TCR-T cells/m2 BSA).
- Immatics has prioritized patient treatment with IMA203 and IMA203CD8 TCR-T monotherapy in the last-line therapy setting.
- Next update on Immatics’ IMA203 Phase 1b cohorts, including the projected clinical development path for PRAME TCR-T monotherapy towards registration-directed trials and potential commercialization is planned for 4Q 2023. Immatics’ IMA203 development strategy to realize the multi-cancer opportunity PRAME is based on two pillars aimed:
- initially at a (1) fast-to-market approach in 1-2 last-line solid cancer types with high PRAME prevalence and where clinical proof-of-concept has been demonstrated, such as cutaneous melanoma (potentially bundled with uveal melanoma) and/or ovarian cancer and
- later at a (2) planned broad development with expansion to other cancer types, such as uterine cancer, lung cancer, breast cancer, head and neck cancer and other tumor types having a broad patient reach.
- Immatics is currently building a state-of-the-art facility designed to manufacture ACTengine® IMA203 TCR-T products, as well as other cell therapy candidates, for registration-directed trials and initial commercial supply. The facility is expected to be operational in 2024.
Autologous TCR-T pipeline
- Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the 2019 multi-target strategic collaboration to develop four TCR-based adoptive cell therapies targeting solid tumors.
- Immatics received an option payment of
$15 million and is eligible for up to$490 million in milestone payments in addition to tiered royalties on net sales of the product.
Immatics’ T cell engaging receptor (TCER®) candidates are next-generation, half-life extended TCR Bispecific molecules designed to maximize efficacy while minimizing toxicities in patients through Immatics’ proprietary format using a low-affinity T cell recruiter and a high-affinity TCR domain.
- TCER® IMA401 (MAGEA4/8) – Phase 1 trial to evaluate safety, tolerability and initial anti-tumor activity of TCER® IMA401 in patients with recurrent and/or refractory solid tumors is ongoing. IMA401 is being developed in collaboration with Bristol Myers Squibb.
- TCER® IMA402 (PRAME) – Immatics submitted a clinical trial application (CTA4) to the Paul-Ehrlich-Institute (PEI) on April 14, 2023, to initiate the Phase 1/2 trial investigating IMA402 in patients with recurrent and/or refractory solid tumors. The trial is expected to commence in 2H 2023 with a first clinical data interim report planned in 2024.
Corporate Update
- Nancy Valente, M.D., resigned from her position on Immatics’ Board of Directors effective May 12, 2023. Nancy has been appointed as Chief Development Officer at Xencor Inc.. Immatics would like to thank Nancy Valente for her valuable contributions during her time on Immatics' Board of Directors.
First Quarter 2023 Financial Results
Cash Position: Cash and cash equivalents as well as other financial assets total
Revenue: Total revenue, consisting of revenue from collaboration agreements, was
Research and Development Expenses: R&D expenses were
General and Administrative Expenses: G&A expenses were
Net Profit and Loss: Net loss was
Upcoming Investor Conferences
- Jefferies Global Healthcare Conference, New York, NY – June 7-9, 2023
- Jefferies London Healthcare Conference, London, U.K. – November 14-16, 2023
To see the full list of events and presentations, visit www.investors.immatics.com/events-presentations.
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on Twitter, Instagram and LinkedIn.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics’ future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics’ focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.
For more information, please contact:
| Media and Investor Relations Contact | |
| Eva Mulder or Charlotte Spitz | |
| Trophic Communications | |
| Phone: +49 151 7441 6179 | |
| immatics@trophic.eu |
| Immatics N.V. | |
| Anja Heuer | Jordan Silverstein |
| Senior Director Corporate Communications | Head of Strategy |
| Phone: +49 89 540415-606 | Phone: +1 281 810 7545 |
| media@immatics.com | InvestorRelations@immatics.com |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Profit/(Loss) of Immatics N.V.
| Three months ended March 31, | ||
| 2023 | 2022 | |
| (Euros in thousands, except share and per share data) | ||
| Revenue from collaboration agreements | 9,796 | 102,907 |
| Research and development expenses | (27,581) | (25,144) |
| General and administrative expenses | (9,586) | (9,278) |
| Other income | 941 | 7 |
| Operating result | (26,430) | 68,492 |
| Change in fair value of liabilities for warrants | 7,397 | 16,528 |
| Other financial income | 2,795 | 1,759 |
| Other financial expenses | (3,509) | (1,117) |
| Financial result | 6,683 | 17,170 |
| Profit/(loss) before taxes | (19,747) | 85,662 |
| Taxes on income | — | — |
| Net profit/(loss) | (19,747) | 85,662 |
| Net profit/(loss) per share: | ||
| Basic | (0.26) | 1.36 |
| Diluted | (0.26) | 1.35 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V.
| Three months ended March 31, | ||
| 2023 | 2022 | |
| (Euros in thousands) | ||
| Net profit/(loss) | (19,747) | 85,662 |
| Other comprehensive income/(loss) | ||
| Items that may be reclassified subsequently to profit or loss | ||
| Currency translation differences from foreign operations | 564 | 560 |
| Total comprehensive income/(loss) for the year | (19,183) | 86,222 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Financial Position of Immatics N.V.
| As of | ||
| March 31, 2023 | December 31, 2022 | |
| (Euros in thousands) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | 117,919 | 148,519 |
| Other financial assets | 211,894 | 213,686 |
| Accounts receivables | 231 | 1,111 |
| Other current assets | 15,011 | 13,838 |
| Total current assets | 345,055 | 377,154 |
| Non-current assets | ||
| Property, plant and equipment | 16,590 | 13,456 |
| Intangible assets | 1,565 | 1,632 |
| Right-of-use assets | 13,010 | 13,033 |
| Other non-current assets | 2,268 | 2,545 |
| Total non-current assets | 33,433 | 30,666 |
| Total assets | 378,488 | 407,820 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Provisions | 1,531 | - |
| Accounts payables | 14,321 | 13,056 |
| Deferred revenue | 64,770 | 64,957 |
| Liabilities for warrants | 9,517 | 16,914 |
| Lease liabilities | 2,453 | 2,159 |
| Other current liabilities | 7,987 | 9,366 |
| Total current liabilities | 100,579 | 106,452 |
| Non-current liabilities | ||
| Deferred revenue | 65,279 | 75,759 |
| Lease liabilities | 12,513 | 12,403 |
| Other non-current liabilities | 33 | 42 |
| Total non-current liabilities | 77,825 | 88,204 |
| Shareholders’ equity | ||
| Share capital | 767 | 767 |
| Share premium | 720,280 | 714,177 |
| Accumulated deficit | (520,046) | (500,299) |
| Other reserves | (917) | (1,481) |
| Total shareholders’ equity | 200,084 | 213,164 |
| Total liabilities and shareholders’ equity | 378,488 | 407,820 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Cash Flows of Immatics N.V.
| Three months ended March 31, | ||
| 2023 | 2022 | |
| (Euros in thousands) | ||
| Cash flows from operating activities | ||
| Net profit/(loss) | (19,747) | 85,662 |
| Taxes on income | — | — |
| Profit/(loss) before tax | (19,747) | 85,662 |
| Adjustments for: | ||
| Interest income | (2,254) | (6) |
| Depreciation and amortization | 1,811 | 1,636 |
| Interest expenses | 195 | 162 |
| Equity settled share-based payment | 6,103 | 5,702 |
| Net foreign exchange differences and expected credit losses | 3,143 | (1,586) |
| Change in fair value of liabilities for warrants | (7,397) | (16,528) |
| Changes in: | ||
| Decrease/(increase) in accounts receivables | 880 | (61) |
| Decrease/(increase) in other assets | 234 | (235) |
| (Decrease)/increase in deferred revenue, accounts payables and other liabilities | (7,793) | 32,800 |
| Interest received | 1,189 | 6 |
| Interest paid | (79) | (162) |
| Income tax paid | — | — |
| Net cash (used in)/provided by operating activities | (23,715) | 107,390 |
| Cash flows from investing activities | ||
| Payments for property, plant and equipment | (4,317) | (1,156) |
| Payments for investments classified in Other financial assets | (67,735) | — |
| Proceeds from maturity of investments classified in Other financial assets | 68,341 | 6,993 |
| Payments for intangible assets | (8) | (2) |
| Proceeds from disposal of property, plant and equipment | — | 1 |
| Net cash (used in)/provided by investing activities | (3,719) | 5,836 |
| Cash flows from financing activities | ||
| Proceeds from issuance of shares to equity holders | — | — |
| Transaction costs deducted from equity | — | — |
| Repayment of lease liabilities | (866) | (689) |
| Net cash (used in)/provided by financing activities | (866) | (689) |
| Net (decrease)/increase in cash and cash equivalents | (28,300) | 112,537 |
| Cash and cash equivalents at beginning of the year | 148,519 | 132,994 |
| Effects of exchange rate changes and expected credit losses on cash and cash equivalents | (2,300) | 1,785 |
| Cash and cash equivalents at end of the year | 117,919 | 247,316 |
Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Changes in Shareholders’ equity (deficit) of Immatics N.V.
| (Euros in thousands) | Share capital | Share premium | Accumulated deficit | Other reserves | Total share- holders’ equity |
| Balance as of January 1, 2022 | 629 | 565,192 | (537,813) | (3,945) | 24,063 |
| Other comprehensive income | — | — | — | 560 | 560 |
| Net profit | — | — | 85,662 | — | 85,662 |
| Comprehensive income for the year | — | — | 85,662 | 560 | 86,222 |
| Equity-settled share-based compensation | — | 5,702 | — | — | 5,702 |
| Share options exercised | — | — | — | — | — |
| Balance as of March 31, 2022 | 629 | 570,894 | (452,151) | (3,385) | 115,987 |
| Balance as of January 1, 2023 | 767 | 714,177 | (500,299) | (1,481) | 213,164 |
| Other comprehensive income | — | — | — | 564 | 564 |
| Net loss | — | — | (19,747) | — | (19,747) |
| Comprehensive loss for the year | — | — | (19,747) | 564 | (19,183) |
| Equity-settled share-based compensation | — | 6,103 | — | — | 6,103 |
| Share options exercised | — | — | — | — | — |
| Issue of share capital – net of transaction costs | — | — | — | — | — |
| Balance as of March 31, 2023 | 767 | 720,280 | (520,046) | (917) | 200,084 |
1 All amounts translated using the exchange rate published by the European Central Bank in effect as of March 31, 2023 (1 EUR = 1.0875 USD).
2 Duration of response (DOR) in confirmed responders is defined as time from first documented response until disease progression/death. Patients with ongoing response will be censored at date of data cut-off. Median DOR is analyzed by using the Kaplan-Meier method.
3 Median follow-up is analyzed by using the reverse Kaplan-Meier method.
4 Clinical Trial Application (CTA) is the European equivalent of an Investigational New Drug (IND) application.
Attachment
